Nuclear Medicine and Biology
Volume 33, Issue 5 , Pages 677-683 , July 2006

An improved method of 18F peptide labeling: hydrazone formation with HYNIC-conjugated c(RGDyK)

  • Yun-Sang Lee

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
    • Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea
    • Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul 110-799, Korea
    • Department of Manufacturing Pharmacy, College of Pharmacy, Seoul National University, Seoul 151-742, Korea
    • ,
  • Jae Min Jeong

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
    • Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea
    • Corresponding Author InformationCorresponding authors. Jae Min Jeong is to be contacted at Department of Nuclear Medicine, Seoul National University College of Medicine, 28 Yongon-dong, Jongno-gu, Seoul 110-744, Korea. Tel.: +82 2 2072 3805; fax: +82 2 745 7690. Young-Ger Suh, Tel.: +82 2 880 7875; fax: +82 2 888 0649.
    • ,
  • Hyung Woo Kim

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
    • Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul 110-799, Korea
    • ,
  • Young Soo Chang

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
    • Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea
    • Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul 110-799, Korea
    • ,
  • Young Joo Kim

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
    • Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea
    • ,
  • Mee Kyung Hong

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
    • Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea
    • ,
  • Ganesha B. Rai

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
    • ,
  • Dae Yoon Chi

      Affiliations

    • Department of Chemistry, Inha University, Inchon 402-751, Korea
    • ,
  • Won Jun Kang

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
    • ,
  • Joo Hyun Kang

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
    • Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea
    • ,
  • Dong Soo Lee

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
    • ,
  • June-Key Chung

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
    • Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea
    • ,
  • Myung Chul Lee

      Affiliations

    • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 110-744, Korea
    • ,
  • Young-Ger Suh

      Affiliations

    • Department of Manufacturing Pharmacy, College of Pharmacy, Seoul National University, Seoul 151-742, Korea
    • Corresponding Author InformationCorresponding authors. Jae Min Jeong is to be contacted at Department of Nuclear Medicine, Seoul National University College of Medicine, 28 Yongon-dong, Jongno-gu, Seoul 110-744, Korea. Tel.: +82 2 2072 3805; fax: +82 2 745 7690. Young-Ger Suh, Tel.: +82 2 880 7875; fax: +82 2 888 0649.

Received 8 February 2006 ,Revised 7 April 2006 ,Accepted 8 April 2006.

References 

  1. Stromblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin αvβ3 during angiogenesis. J Clin Invest. 1996;98:426–433
  2. Byzova TV, Rabbani R, D'Souza SE, Plow EF. Role of integrin alpha(v)-beta3 in vascular biology. Thromb Haemost. 1998;80:726–734
  3. Eliceiri BP, Cheresh DA. The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest. 1999;103:1237–1241
  4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257
  5. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science. 1987;238:491–497
  6. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest. 1995;96:1815–1822
  7. Sheu JR, Yen MH, Kan YC, Hung WC, Chang PT, Luk HN. Inhibition of angiogenesis in vitro and in vivo: comparison of the relative activities of triflavin, an Arg–Gly–Asp-containing peptide and anti-αvβ3 integrin monoclonal antibody. Biochim Biophys Acta. 1997;1336:445–454
  8. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157–1164
  9. Allman R, Cowburn P, Mason M. In vitro and in vivo effects of a cyclic peptide with affinity for the αvβ3 integrin in human melanoma cells. Eur J Cancer. 2000;36:410–422
  10. Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H, et al. Radiolabeled αvβ3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med. 1999;40:1061–1071
  11. Liu S, Cheung E, Rajopadhye M, Williams NE, Overoye KL, Edwards DS. Isomerism and solution dynamics of 90Y-labeled DTPA-biomolecule conjugates. Bioconjug Chem. 2001;12:84–91
  12. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001;42:326–336
  13. Janssen ML, Oyen WJ, Dijkgraaf I, Massuger LF, Frielink C, Edwards DS, et al. Tumor targeting with radiolabeled αvβ3 integrin binding peptides in a nude mouse model. Cancer Res. 2002;62:6146–6151
  14. Su ZF, Liu G, Gupta S, Zhu Z, Rusckowski M, Hnatowich DJ. In vitro and in vivo evaluation of a technetium-99m-labeled cyclic RGD peptide as a specific marker of αvβ3 integrin for tumor imaging. Bioconjug Chem. 2002;13:561–570
  15. Chen X, Park R, Tohme M, Shahinian AH, Bading JR, Conti PS. MicroPET and autoradiographic imaging of breast cancer αv-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem. 2004;15:41–49
  16. Poethko T, Schottelius M, Thumshirn G, Hersel U, Herz M, Henriksen G, et al. Two-step methodology for high-yield routine radiohalogenation of peptides: 18F-labeled RGD and octreotide analogs. J Nucl Med. 2004;45:892–902
  17. Chen X, Park R, Shahinian AH, Tohme M, Khankaldyyan V, Bozorgzadeh MH, et al. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol. 2004;31:179–189
  18. Kim JS, Lee KC, Lee BC, Moon BS, Song HJ, Chun KS, et al. Synthesis of fluorine-18 labeled glucose–Lys–Arg–Gly–Asp–D-Phe as a potential tumor imaging agent. J Label Compd Radiopharm. 2005;48:S289
  19. Okarvi SM. Recent progress in fluorine-18 labelled peptide radiopharmaceuticals. Eur J Nucl Med. 2001;28:929–938
  20. Varagnolo L, Stokkel MPM, Mazzi U, Pauwels EKJ. 18F-labeled radiopharmaceuticals for PET in oncology, excluding FDG. Nucl Med Biol. 2000;27:103–112
  21. Haka MS, Kilbourn MR, Watkins GL, Toorongian SA. Aryltrimethylammonium trifluoromethanesulfonates as precursors to aryl [18F]fluorides: improved synthesis of [18F]GBR-13119. J Label Compd Radiopharm. 1989;27:823–838
  22. Vaidyanathan G, Zalutsky MR. Labeling proteins with fluorine-18 using N-succinimidyl 4-[18F]fluorobenzoate. Nucl Med Biol. 1992;19:275–281
  23. Wester HJ, Hamacher K, Stocklin G. A comparative study of n.c.a fluorine-18 labeling of proteins via acylation and photochemical conjugation. Nucl Med Biol. 1996;23:365–372
  24. Downer JB, McCarthy TJ, Edwards WB, Anderson CJ, Welch MJ. Reactivity of p-[18F]fluorophenacyl bromide for radiolabeling of proteins and peptides. Appl Radiat Isot. 1997;48:907–916
  25. Iwata R, Pascali C, Bogni A, Horvath G, Kovacs Z, Yanai K, et al. A new, convenient method for the preparation of 4-[18F]fluorobenzyl halides. Appl Radiat Isot. 2000;52:87–92
  26. Vries EFJ, Vroegh J, Elsinga PH, Vaalburg W. Evaluation of fluorine-18-labeled alkylating agents as potential synthons for the labeling of oligonucleotides. Appl Radiat Isot. 2003;58:469–476
  27. Chang YS, Jeong JM, Lee Y-S, Kim HW, Rai GB, Lee SJ, et al. Preparation of 18F-human serum albumin: a simple and efficient protein labeling method with 18F using a hydrazone-formation method. Bioconjug Chem. 2005;16:1329–1333
  28. Couffinhal T, Silver M, Zheng LP, Kearney M, Witzenbichler B, Isner JM. Mouse model of angiogenesis. Am J Pathol. 1998;152:1667–1679
  29. Lee K-H, Jung K-H, Song S-H, Kim DH, Lee BC, Sung HJ, et al. Radiolabeled RGD uptake and αv integrin expression is enhanced in ischemic murine hindlimbs. J Nucl Med. 2005;46:472–478
  30. Chen X, Park R, Shahinian AH, Bading JR, Conti PS. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol. 2004;31:11–19
  31. Kouns WC, Kirchhofer D, Hadvary P, Edenhofer A, Weller T, Pfenninger G, et al. Reversible conformational changes induced in glycoprotein IIb–IIIa by a potent and selective peptidomimetic inhibitor. Blood. 1992;80:2539–2547
  32. Pytela R, Pierschbacher MD, Argraves S, Suzuki S, Ruoslahti E. Arginine–glycine–aspartic acid adhesion receptors. Methods Enzymol. 1987;144:475–489
  33. Abrams MJ, Juweid M, tenKate CI, Schwartz DA, Hauser MM, Gaul FE, et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med. 1990;31:2022–2028
  34. Schwartz DA, Abrams MJ, Hauser MM, Gaul FE, Larsen SK, Rauh D, et al. Preparation of hydrazino-modified proteins and their use for the synthesis of 99mmTc–protein conjugates. Bioconjug Chem. 1991;2:333–336
  35. Babich JW, Graham W, Barrow SA, Fischman AJ. Comparison of the infection imaging properties of a 99mTc labeled chemotactic peptide with 111In IgG. Nucl Med Biol. 1995;22:643–648
  36. Decristoforo C, Mather SJ. Preparation, 99mTc-labeling, and in vitro characterization of HYNIC and N3S modified RC-160 and [Tyr3]octreotide. Bioconjug Chem. 1999;10:431–438
  37. Greenland WEP, Howland K, Hardy J, Fogelman I, Blower PJ. Solid-phase synthesis of peptide radiopharmaceuticals using Fmoc-N-E-(Hynic-Boc)-lysine, a technetium-binding amino acid: application to Tc-99m-labeled salmon calcitonin. J Med Chem. 2003;46:1751–1757
  38. King TP, Zhao SW, Lam T. Preparation of protein conjugates via intermolecular hydrazone linkage. Biochemistry. 1986;25:5774–5779
  39. Jeong JM, Lee J, Paik CH, Kim DK, Lee DS, Chung J-K, et al. Site-specific 99mTc-labeling of antibody using dihydrazinophthalazine (DHZ) conjugation to Fc region of heavy chain. Arch Pharm Res. 2004;27:961–967
  40. Silva AG, Zapata-Sudo G, Kummerle AE, Fraga CAM, Barreiro EJ, Sudo RT. Synthesis and vasodilatory activity of new N-acylhydrazone derivatives, designed as LASSBio-294 analogues. Bioorg Med Chem. 2005;13:3431–3437
  41. Uppadine LH, Gisselbrecht J-P, Kyritsakas N, Nattinen K, Rissanen K, Lehn J-M. Mixed-valence, mixed-spin-state, and heterometallic [2×2] grid-type arrays based on heteroditopic hydrazone ligands: synthesis and electrochemical features. Chem Eur J. 2005;11:2549–2565

PII: S0969-8051(06)00070-9

doi: 10.1016/j.nucmedbio.2006.04.004

Nuclear Medicine and Biology
Volume 33, Issue 5 , Pages 677-683 , July 2006

Article Tools

* Image Usage & Resolution